Previous 10 | Next 10 |
AcelRx Pharmaceuticals (NASDAQ: ACRX ) downgraded to Neutral with a $2 (3% upside) price target at Credit Suisse. Shares down 3% premarket. More news on: AcelRx Pharmaceuticals, Inc., CytomX Therapeutics, Inc., Wright Medical Group N.V., Healthcare stocks news, Stocks on the mo...
AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2019 Earnings Conference Call November 06, 2019, 05:00 PM ET Company Participants Raffi Asadorian - CFO Vince Angotti - CEO Pam Palmer - Chief Medical Officer and Co-Founder Charles Lee - Board Certified Plastic and Reconstructive Surgeon ...
Image source: The Motley Fool. AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) Q3 2019 Earnings Call Nov 6, 2019 , 5:00 p.m. ET Operator Continue reading
AcelRx Pharmaceuticals (NASDAQ: ACRX ): Q3 GAAP EPS of -$0.16 beats by $0.06 . Revenue of $0.61M (+60.5% Y/Y) misses by $0.35M . Cash & equivalents $80.4M. Shares +7.3% . Press Release More news on: AcelRx Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the ...
REDWOOD CITY, Calif. , Nov. 6, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its third qu...
REDWOOD CITY, Calif. , Nov. 5, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management w...
REDWOOD CITY, Calif. , Oct. 28, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Wednesday, November 6, 2019 . AcelRx management will host ...
REDWOOD CITY, Calif. , Oct. 16, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming pre...
Editor's note: Seeking Alpha is proud to welcome Stephan Otzen as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » AcelRx Pharmaceutic...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 120 weeks of public selections as part of this ongoing live forward-testing. In...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...